Impact of young age on treatment efficacy and safety in advanced colorectal cancer: A pooled analysis of patients from nine first-line phase III chemotherapy trials

Journal of Clinical Oncology

Volumn 29, Issue 20, 2011, Pages 2781-2786

  Blanke, Charles D ^a   Bot, Brian M ^b   Thomas, David M ^c   Bleyer, Archie ^d   Kohne, Claus Henning ^e   Seymour, Matthew T ^f   De Gramont, Aimery ^g   Goldberg, Richard M ^h   Sargent, Daniel J ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b MAYO CLINIC   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d ST CHARLES MEDICAL CENTER   (United States)

^e Clinic for Oncology and Hematologie   (Germany)

^f UNIVERSITY OF LEEDS   (United Kingdom)

^g HÔPITAL SAINT ANTOINE   (France)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ADVANCED COLORECTAL CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GROUPS BY AGE; HUMAN; META ANALYSIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STOMATITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DIARRHEA; DRUG TOXICITY; FLUOROURACIL; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; STOMATITIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79960273720     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.5281     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2008. CA Cancer J Clin 58:71-96, 2008
3. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch: Surveillance, epidemiology, and end results (SEER 17) program populations, November 2009. http://www.seer.cancer.gov/popdata
4. Mandelblatt J, Andrews H, Kao R, et al: The late-stage diagnosis of colorectal cancer: Demographic and socioeconomic factors. Am J Public Health 86:1794-1797, 1996
5. Folprecht G, Cunningham D, Ross P, et al: Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 15:1330-1338, 2004 (Pubitemid 39302467)
6. O'Connell JB, Maggard MA, Liu JH, et al: Do young colon cancer patients have worse outcomes? World J Surg 28:558-562, 2004
7. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-818, 2005
8. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3226, 2010
9. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
10. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 355:1041-1047, 2000 (Pubitemid 30162806)
11. Seymour MT, Maughan TS, Ledermann JA, et al: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomized controlled trial. Lancet 370:143-152, 2007 (Pubitemid 47042894)
12. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004 (Pubitemid 41095110)
13. Köhne CH, van Cutsem E, Wils J, et al: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group study 40986. J Clin Oncol 23: 4856-4865, 2005 (Pubitemid 46223990)
14. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - A GERCOR study. J Clin Oncol 24:394-400, 2006 (Pubitemid 46630458)
15. Porschen R, Arkenau HT, Kubicka S, et al: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO Colorectal Study Group. J Clin Oncol 25:4217-4223, 2007 (Pubitemid 47548561)
16. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan study group. N Engl J Med 343:905-914, 2000
17. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
18. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
19. Hosmer DA, Lemeshow S: Applied Logistic Regression. John Riley and Sons, 1989, 216-245
20. National Cancer Institute Common Toxicity Criteria, Version 2.0. http://ctep.info.nih.gove/protocolDevelopment/electronic-applications/ctc.htm
21. Boissel N, Auclerc MF, Lhéritier V, et al: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21:774-780, 2003 (Pubitemid 46606434)
22. Bleyer A, Montello M, Budd T, et al: National survival trends of young adults with sarcoma: Lack of progress is associated with lack of clinical trial participation. Cancer 103:1891-1897, 2005
23. Bertagnolli MM, Niedzwiecki D, Compton CC, et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27:1814-1821, 2009
24. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085-4091, 2006 (Pubitemid 46622283)
25. Falcone A, Ricci S, Brunetti I, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670-1676, 2007 (Pubitemid 46797946)